Table 3.
Association between aspirin use1 and risk for developing incident advanced fibrosis/cirrhosis2, among patients with NAFLD fibrosis stage 0-2 at enrollment (n=317)
| Indices of advanced fibrosis2 | Non-Regular Aspirin Use (ref.) N=184 |
Daily Aspirin Use1 N=133 |
|---|---|---|
| Composite2 | ||
| No. with endpoint | 54 | 32 |
| Age- and sex-adjusted* HR (95% CI) | 1 | 0.66 (0.49-0.84) |
| Multivariable Model¥; HR (95% CI) | 1 | 0.63 (0.43-0.85) |
| FIB-4 > 2.67 | ||
| No. with endpoint | 52 | 29 |
| • Age- and sex-adjusted* HR (95% CI) | 1 | 0.66 (0.51-0.86) |
| • Multivariable Model¥; HR (95% CI) | 1 | 0.61 (0.42-0.89) |
| NFS > 0.676 | ||
| No. with endpoint | 50 | 31 |
| • Age- and sex-adjusted* HR (95% CI) | 1 | 0.64 (0.49-0.85) |
| • Multivariable Model¥; HR (95% CI) | 1 | 0.53 (0.38-0.72) |
| APRI > 1.0 | ||
| No. with endpoint | 33 | 16 |
| • Age- and sex-adjusted* HR (95% CI) | 1 | 0.65 (0.51-0.85) |
| • Multivariable Model¥; HR (95% CI) | 1 | 0.61 (0.43-0.87) |
Abbreviations: NAFLD, nonalcoholic fatty liver disease; HR, hazard ratio; CI, confidence interval; NFS, NAFLD Fibrosis Score; APRI, aspartate aminotransferase-to-platelet ratio; FIB-4, fibrosis-4
Model 1: adjusted for age (years), sex, biopsy calendar year and number of follow-up visits.
Multivariable Model: Model 1 + Hispanic ethnicity, BMI (continuous kg/m2), diabetes, hypertension, hyperlipidemia, smoking history (current vs. prior vs. never), coronary artery disease, statin use and metformin use.
Aspirin use was defined as daily use; less frequent or never-use was defined as non-regular use. Aspirin use data was updated at each follow-up visit and modeled as a time-varying exposure.
Incident advanced fibrosis (i.e. stage 3 or 4 fibrosis; composite endpoint) was defined as the first recorded FIB4 > 2.67, or NAFLD Fibrosis Score > 0.676, or APRI > 1.0 during study follow-up.